Absorption Pharmaceuticals Announces 10,000 Bottles of PROMESCENT Sold

Share Article

Topical solution for premature ejaculation welcomed by physicians and patients

PROMESCENT metered dose spray bottle

Now, for the first time, healthcare professionals have an effective product to recommend that is specifically formulated for the treatment of PE

Absorption Pharmaceuticals announced today that it has sold its ten thousandth bottle of PROMESCENT, a patented topical solution specifically formulated for the treatment of premature ejaculation (PE). PE is a common sexual health problem that can significantly impact an individual and his partner’s well-being, potentially causing psychological and emotional distress. Currently, PE is treated off-label with selective serotonin reuptake inhibitors (SSRI's) and with desensitizing topical agents—both have their drawbacks. SSRI's have unwanted side effects and other topicals lack the absorption technology needed to achieve a fast-acting, controllable dose.

Since its launch in May 2011, PROMESCENT has gained wide acceptance by the medical community as an effective treatment alternative. Engineered to have markedly improved skin penetration compared to other topicals, PROMESCENT has been found to have no serious side effects. The company is hosting an invitation only dinner with a presentation by the renowned sexual medicine specialist Dr. Irwin Goldstein, at the Sexual Medicine Society of North America annual meeting this month.

CEO Jeff Abraham stated, “Since our launch at the American Urological Association (AUA) meeting last May, we’ve seen rapid adoption—demand for PROMESCENT has increased beyond expectations. Our commitment to delivering a true medical solution for this troublesome condition has earned us the approval and acceptance of healthcare professionals and their patients.”
Company founder and Chief Medical Officer, Dr. Ronald Gilbert added, “Now, for the first time, healthcare professionals have an effective product to recommend that is specifically formulated for the treatment of PE. Estimates vary, but it’s thought that 1 in every 3 men may be affected at some time. With the upcoming completion of our initial clinical trial, we have reason to believe that PROMESCENT will become the standard of care for all PE related treatment paradigms.”

Having conferred with several authors of the AUA guidelines for treating PE, Harpreet Sheridan, Vice President of Sales at Absorption Pharmaceuticals, was invited to attend the International Men's Health Congress in Vienna last month. Ms. Sheridan noted, “The global medical community was as receptive as they have been in the States and it’s been reflected in our increased inquiries and sales.”

Absorption Pharmaceuticals will be participating in several upcoming medical conferences, including the Sexual Medicine Society of North America (SMSNA), the European society of sexual medicine congress, the American Association of Sexuality Educators, Counselors and Therapists (AASECT) and the World Meeting on Sexual Medicine. PROMESCENT is available in a metered-dose spray bottle on-line and directly from urologists and therapists in the United States and Puerto Rico.

About Absorption Pharmaceutials LLC
Created by Absorption Pharmaceuticals, PROMESCENT, is a specially-formulated topical anesthetic for premature ejaculation. Developed by pharmacologists and urologists, PROMESCENT’s absorption technology, in conjunction with the metered-dose spray bottle, enables men to deliver a specific and reproducible amount of lidocaine through the stratum corneum and dermis of the penis to control ejaculation latency. PROMESCENT allows men to easily manage penile sensitivity in order to maintain optimum sexual satisfaction.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nick Abraham
Visit website